How can we explain the sudden 30% decrease in sponsor adoption of Science 37's mobile nursing services in the past 6 weeks?

Introduction

The sudden 30% decrease in sponsor adoption of Science 37's mobile nursing services over the past 6 weeks is a critical issue that demands immediate attention. This analysis will systematically identify, validate, and address the root cause while considering both short-term and long-term implications for the product and business.

To tackle this problem, I'll follow a structured approach that covers issue identification, hypothesis generation, validation, and solution development. My goal is to provide a comprehensive analysis that not only addresses the immediate concern but also strengthens our product strategy moving forward.

Step 1

Clarifying Questions (3 minutes)

• Looking at the timing, I'm thinking there might have been a recent change in our service offering. Have we introduced any new features or pricing models in the last 2-3 months?

Why it matters: Recent changes could directly impact adoption rates. Expected answer: Yes, we launched a new pricing tier. Impact on approach: If true, we'd focus on analyzing the new pricing structure's impact.

• Considering the specificity of the decrease, I'm wondering about our measurement accuracy. Has there been any change in how we track or define "sponsor adoption" recently?

Why it matters: Ensures we're addressing a real issue, not a measurement anomaly. Expected answer: No changes in measurement. Impact on approach: If there were changes, we'd need to reassess our data integrity first.

• Given the magnitude of the decrease, I'm curious about market conditions. Have there been any significant changes in the clinical trial landscape or competitor offerings recently?

Why it matters: External factors could be driving the decrease. Expected answer: No major market shifts noted. Impact on approach: If market changes are identified, we'd need to consider broader industry trends in our analysis.

• Thinking about user segments, I'm wondering if this decrease is uniform across all sponsor types. Can we break down the adoption rates by sponsor size or therapeutic area?

Why it matters: Helps identify if the issue is global or specific to certain segments. Expected answer: The decrease varies across segments. Impact on approach: If segmented, we'd focus on the most affected groups and tailor our solutions accordingly.